Fibroblast Growth Factor 2 Fgfr2 Pipeline Insight
DelveInsight’s, “Fibroblast Growth Factor 2 (FGFR2) – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Fibroblast Growth Factor 2 (FGFR2) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Fibroblast Growth Factor 2 (FGFR2) Understanding
Fibroblast Growth Factor 2 (FGFR2): Overview
Fibroblast growth factor receptor 2 (FGFR2) also known as CD332 (cluster of differentiation 332) is a protein that in humans is encoded by the FGFR2 gene residing on chromosome 10. FGFR2 is a receptor for fibroblast growth factor.
Structure and Signaling of the FGFR2 Receptor
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform.
FGFR2 has important roles in embryonic development and tissue repair, especially bone and blood vessels. Like the other members of the fibroblast growth factor receptor family, these receptors signal by binding to their ligand and dimerisation (pairing of receptors), which causes the tyrosine kinase domains to initiate a cascade of intracellular signals. On a molecular level these signals mediate cell division, growth and differentiation.
FGFR2 has two naturally occurring isoforms, FGFR2IIIb and FGFR2IIIc, created by splicing of the third immunoglobulin-like domain. FGFR2IIIb is predominantly found in ectoderm derived tissues and endothelial organ lining, i.e. skin and internal organs. FGFR2IIIc is found in mesenchyme, which includes craniofacial bone and for this reason the mutations of this gene and isoform are associated with craniosynostosis.
Fibroblast Growth Factor 2 (FGFR2) Emerging Drugs Chapters
This segment of the Fibroblast Growth Factor 2 (FGFR2) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibroblast Growth Factor 2 (FGFR2) Emerging Drugs
- FPA144 (Bemarituzumab): Five Prime Therapeutics
Bemarituzumab (also known as FPA144) is a first-in-class FGFR2b antibody in clinical development as a targeted immune therapy for tumors that over-express FGFR2b. There are currently no other FGFR2b-specific antibodies in the clinic. Because it is specific for FGFR2b, it does not affect in normal cell processes, like metabolic regulation, glucose and phosphate regulation. This antibody is designed to block tumor growth through two distinct mechanisms:
- It binds specifically to FGFR2b and prevents the binding of certain fibroblast growth factors that promote tumor growth
- It has been engineered to drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity through the recruitment of natural killer cells
- Alofanib: Russian Pharmaceutical Technologies
Alofanib is an allosteric inhibitor of FGFR2 and significantly inhibited bFGF-induced proliferation of HUVEC cells (IC50 value of 11 nM) and suppressed proliferation of SVEC-4-10 cells (IC50 value of 58 nM). Moreover, Alofanib suppressed the migration activity of endothelial cells, and their ability to form vessel-like structures in vitro. Also, Alofanib significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo.
Further product details are provided in the report……..
Fibroblast Growth Factor 2 (FGFR2): Therapeutic Assessment
This segment of the report provides insights about the different Fibroblast Growth Factor 2 (FGFR2) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Fibroblast Growth Factor 2 (FGFR2)
There are approx. 10+ key companies which are developing the therapies for Fibroblast Growth Factor 2 (FGFR2). The companies which have their Fibroblast Growth Factor 2 (FGFR2) drug candidates in the most advanced stage, i.e. phase II include, Ribomic, DNAVEC Corporation etc.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Fibroblast Growth Factor 2 (FGFR2) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Fibroblast growth factor replacements
- Small molecules
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Fibroblast Growth Factor 2 (FGFR2): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Growth Factor 2 (FGFR2) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Growth Factor 2 (FGFR2) drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Fibroblast Growth Factor 2 (FGFR2) R&D. The therapies under development are focused on novel approaches to treat/improve Fibroblast Growth Factor 2 (FGFR2).
- August 2020: SKI-O-703 (FGFR2 inhibitor) is currently undergoing two Phase 2 clinical trials in rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura (ITP).
Fibroblast Growth Factor 2 (FGFR2) Report Insights
- Fibroblast Growth Factor 2 (FGFR2) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Fibroblast Growth Factor 2 (FGFR2) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Fibroblast Growth Factor 2 (FGFR2) drugs?
- How many Fibroblast Growth Factor 2 (FGFR2) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibroblast Growth Factor 2 (FGFR2)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibroblast Growth Factor 2 (FGFR2) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fibroblast Growth Factor 2 (FGFR2) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Anaeropharma Science Inc.
- Aurealis Therapeutics AG
- ID Pharma Co Ltd.
- NeuBase Therapeutics Inc.
- Ribomic Inc.
- Yantai RC-Pharmaceutical Co Ltd.
- Zucero Therapeutics Ltd.
- Fusion Protein to Inhibit FGF-2 for Cancer
- Gene Therapy to Activate FGF2 for Critical Limb Ischemia